doxepin

(redirected from Silenor)
Also found in: Dictionary, Thesaurus.
Related to Silenor: doxepin

doxepin

 [dok´sĕ-pin]
a tricyclic antidepressant, administered orally as the hydrochloride salt to treat depression, anxiety, chronic pain, peptic ulcer, pruritus, and other conditions.

doxepin

/dox·e·pin/ (dok´sĕ-pin) a tricyclic antidepressant of the dibenzoxepine class; also used to treat chronic pain, peptic ulcer, pruritus, and idiopathic cold urticaria, administered as the hydrochloride salt.

doxepin

(dŏk′sə-pĭn′)
n.
A tricyclic drug, C19H21NO, used in its hydrochloride form orally to treat depression and anxiety and as a cream to relieve itching.

Doxepin®

Zonalon® Pharmacology A tricyclic antidepressant, see there.

doxepin

A TRICYCLIC ANTIDEPRESSANT DRUG. A brand name is Sinequan.

doxepin (topical)

(dok´səpin),
n brand name: Zonolon;
drug class: topical antipruritic (tricyclic antidepressant);
action: antipruritic mechanism unknown; has antihistaminic activity; also produces drowsiness;
uses: pruritus associated with eczema, atopic dermatitis, lichen simplex chronicus.

doxepin

a tricyclic antidepressant and potent histamine H1-receptor blocker, similar to amitriptyline, used in the treatment of psychogenic dermatitis in dogs and cats.
References in periodicals archive ?
Patients should only take Silenor when they are prepared to get a full night's sleep.
Expenses related to Silenor development work also decreased because a higher level of activity relating to the preparation of the NDA and the conduct of non-clinical studies was ongoing during the first quarter of 2008 compared to the first quarter of 2009.
About SILENOR SILENOR is a prescription sleep medicine that is used to treat people with insomnia who have trouble staying asleep.
Pascoe, Somaxon's President and Chief Executive Officer, said, "We believe this acquisition will provide the opportunity to more fully capitalize on the Silenor brand.
has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for Silenor for the treatment of insomnia.
This transaction helps us further our goal of maximizing the value of Silenor for our stockholders by selectively licensing rights to the product outside of the U.
We will also continue to work with our strategic advisor, Stifel Nicolaus Weisel, to evaluate strategic alternatives with the goal of fully leveraging Silenor for the benefit of our stockholders," continued Mr.
Under the terms of the settlement agreement, Mylan has the exclusive right to market an authorized generic version of Silenor for a 180-day period starting January 1, 2020, or earlier under certain pre-specified circumstances.
According to the terms of the settlement agreement, Mylan has the exclusive right to sell an authorized generic version of Silenor in the U.
While we are conducting this process, we will continue to market Silenor in the U.
First Phase III trial: Silenor demonstrates statistically significant improvement in sleep maintenance among adults with chronic insomnia 199